

# Optimising BORTEZOMIB and/or LENALIDOMIDE for Newly-Diagnosed Multiple Myeloma

## FRAIL-M / AMaRC 19-01/ ALLG MM22 Study



The Australasian Myeloma Research Consortium (AMaRC) in collaboration with the Australasian Leukaemia & Lymphoma Group (ALLG) and the Myeloma and Related Diseases Registry (MRDR) is conducting a phase II study to investigate the **optimal usage** of **lenalidomide and/or bortezomib in newly-diagnosed transplant-ineligible myeloma** patients based on a *frailty score* (frailty is characterised by a decline in body functions).

The findings from this study will:

- Provide a robust framework for **optimisation of treatment** in improved survival and preservation of quality of life (QoL) for transplant ineligible myeloma patients.
- Inform more **cost-effective utilisation** of publicly funded high-cost front-line anti-myeloma therapeutics such as bortezomib and lenalidomide, separately to in combination together.
- The **combination of bortezomib and lenalidomide is currently not reimbursed** by PHARMAC.

If you are a patient recently diagnosed with myeloma or a haematologist and would like to know more about this study, then please contact AMaRC at [amarc@alfred.org.au](mailto:amarc@alfred.org.au) for general information.



### About AMaRC

The Australasian Myeloma Research Consortium (AMaRC) is a not-for-profit myeloma clinical trial research group and is a collaboration of myeloma experts, scientists, other clinical specialists to develop and conduct doctor-led myeloma trials in Australia and New Zealand.

We aim to conduct early phase proof-of-concept studies, trialing new treatment combinations and therapies for myeloma, so we can identify those that show the most promise and deserve further research in bigger trials. We also strive for a holistic approach in researching by incorporating correlative science and health economic data collection, where possible.

Our members are part of a large haematology network, who work at the bedside providing high quality medical care, whilst providing their patients with information about the latest research and opportunities to participate in clinical trials. Our goal is to improve the quality of life and survival of patients living with multiple myeloma and ultimately, find a cure.

